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December 2003. Patients were stratiﬁed into 2 cohorts: those
receiving OAB pharmacotherapy, including long-acting toltero-
dine or immediate- or extended-release oxybutynin and those
receiving non-pharmacologic management. Patients were
matched 1 :1 by the estimated propensity score for OAB phar-
macotherapy using a logistic regression model incorporating
selected demographic and clinical characteristics. Differences in
direct medical costs during follow-up were assessed using
descriptive statistics (Wilcoxon rank-sum tests) and multivariate
statistical techniques to adjust for differences in demographic
and clinical characteristics. RESULTS: A total of 1681 matched
pairs were identiﬁed. Patients’ mean ± SD age was 78 ± 8 years;
60% were women. After matching, all initial differences in
patient characteristics were not signiﬁcant. Mean ± SD OAB-
related costs ($244 ± $1763 for PT vs $857 ± $4438 for NPM;
p < 0.0001) and infection-related costs ($860 ± $6265 for PT vs
$1044 ± $6918 for NPM; p < 0.0001) were signiﬁcantly higher
in the NPM cohort compared with the PT cohort while depres-
sion-related ($245 ± $2755 for PT vs $229 ± $2319 for NPM;
p = NS) and fall/fracture-related costs ($380 ± $3115 for PT vs
$554 ± $4142 for NPM, p = NS) were similar. Pharmacy costs
were higher in the PT cohort, but total direct costs (OAB-related
and unrelated) were higher in the NPM group ($11,580 ±
$23,452 for PT vs $12,941 ± $21,938 for NPM; p = NS). After
adjusting for prognostic factors, total direct costs were signiﬁ-
cantly higher for NPM patients in multivariate analyses (p =
0.0091). CONCLUSIONS: Elderly patients receiving OAB phar-
macotherapy appear to have lower annual direct medical costs
compared with patients receiving non-pharmacologic manage-
ment. Careful consideration should be given to the selection 
of OAB treatment options from both clinical and economic 
perspectives.
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OBJECTIVES: The National Kidney Foundation’s Kidney
Disease Outcomes Quality Initiative Guidelines (K/DOQI) rec-
ommend monitoring intact parathyroid hormone levels (iPTH)
among patients with chronic kidney disease (CKD) whose GFR
falls between 15 and 59mL/min/1.73m2. Target ranges for iPTH
levels in CKD are based on expert opinion: patients in stage 3
should not exceed 70pg/mL; patients in stage 4 should not
exceed 110pg/mL. We investigated the shape of the relation
between iPTH levels and health care costs to offer evidence.
METHODS: We assembled a cohort of 830 HMO members
(1998–2004) with stage 3 or 4 CKD (using K/DOQI criteria) and
an iPTH test to measure health care costs in the year following
their index iPTH test. Costs were assigned by applying standard
unit costs to utilization. We compared the ratio of costs 
(geometric means) for quintiles of iPTH using natural log-
transformed, linear regression. RESULTS: Costs increased for
patients who exceeded one of the K/DOQI cut-offs for “ele-
vated” iPTH (110pg/mL), but costs in the highest quintiles of
iPTH were comparable to those in the lowest quintiles. Com-
pared with patients at or below the 20th percentile of iPTH (3
to 55pg/mL), we identiﬁed the following levels of relative excess
(or lower) cost: Percentile (GFR);95% CI;Range 21st to 40th
(56–99); +25%; -18% to +89% 41st to 60th (100–144); +50%;
-2% to +131% 61st to 80th (145–228); +1%; -47% to +30%.
Our estimates controlled for age, sex, most recent estimated GFR
(MDRD), annual cost before the index iPTH value, and mortal-
ity. CONCLUSIONS: iPTH levels predict cost, but not in the
expected dose-response relation; future studies should explore
why the rates of utilization were lower among patients with the
highest levels of iPTH.
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OBJECTIVE: To evaluate current epoetin alfa (EPO) and dar-
bepoetin alfa (DARB) dosing patterns from 2004–2005 in
anemic pre-dialysis chronic kidney disease (CKD) patients receiv-
ing care in nephrology clinics. METHODS: A random panel of
approximately 250 nephrologists was requested bimonthly to
review the medical records of their last two anemic pre-dialysis
CKD patients seen who were currently receiving an erythro-
poiesis-stimulating therapy (EST). Data on patient demograph-
ics, co-morbid conditions, CKD status, EST dose, and frequency
of administration were collected every 2 months to evaluate
changes over time. RESULTS: A total of 943 patient charts were
reviewed from November 2004 through September 2005 (EPO:
528; DARB: 415). Patient demographics, comorbid conditions,
baseline hemoglobin, and renal function were similar between
groups. Weekly and extended (≥Q2W) dosing patterns were seen
in both groups (EPO: QW, 47%; Q2W, 32%; Q4W, 15%; Other,
5%; DARB: QW, 23%; Q2W, 41%; Q4W, 33%; Other, 3%).
The mean weekly doses over the course of the study (EPO:
10,302 units; DARB: 47mcg) corresponded to a dose only ratio
(units EPO: mcg DARB) of 219 :1, resulting in mean weekly
costs of $125 and $205 for EPO and DARB (based on 2005
wholesale acquisition costs), respectively. These weekly cost dif-
ferences were observed in patients both under and over the age
of 65. CONCLUSIONS: DARB was associated with a higher
mean weekly EST cost compared to EPO. These analyses can
guide healthcare providers and decision makers in recognizing
real-world dosing patterns and costs of ESTs for the treatment
of anemic pre-dialysis CKD patients.
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OBJECTIVE: A reauthorization program was implemented to
apply updated VA guidelines to identify patients that may be
maintained on less costly, equally efﬁcacious alternatives for
treatment of benign prostatic hypertrophy. Study objective is to
assess patient safety, effectiveness and costs incurred to direct
formulary policy post implementation. METHODS: This retro-
spective outcome and utilization analysis extracted patient, pre-
scription, and resource data speciﬁc to VASDHS. Eligible
patients required a current prescription for tamsulosin and a
reauthorization request submitted between March and July
2005. Denied requests underwent a retrospective chart review of
the 90-days following the submission while 90-day drug and
resource cost estimates were applied to those requests approved.
Outcomes of denials were reviewed for safety and effectiveness.
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Safety was characterized by ADR reporting and discontinuation
of treatment. Medication effectiveness was determined by per-
sistence on the subsequent alternative alpha1-antagonist.
RESULTS: Of 226 patient requests submitted, 55 (24.3%) were
denied. Patients averaged 17.9 months (±12.4) on tamsulosin
prior to denial. After 90-days, 67.3% remained on the recom-
mended alternative alpha1-antagonist, 14.5% had no alternative
ordered and no tamsulosin dispensed, 9.1% remained on 
tamsulosin from VASDHS, 5.5% continued tamsulosin from
non-VASDHS sources, 3.6% required changing to a second 
non-tamsulosin alternative, and adverse events occurred in
9.1%. The cost of a prescriber entering a reauthorization request
was $8.19/patient while adjudication by a pharmacist was
$11.61/patient. Few telephone contacts(10), unscheduled clinic
visits(1), and urgent care visits(0) occurred adding $5.29 per
patient per month (PPPM). Prescription costs were $9.82 PPPM
for patients denied versus an estimated $43.87 for those
approved. The total cost of 226 requests, excluding scheduled
clinic visits, was $128.94/patient versus an estimated
$131.58/patient if the program had not been implemented.
CONCLUSION: Overall outcomes and associated costs incurred
in a tamsulosin reauthorization program eliminated much of the
anticipated cost savings in the 90-days following a denial.
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OBJECTIVE: Early care provided by nephrologists before ini-
tiating dialysis may improve treatment outcomes for patients
who later progress to end-stage renal disease (ESRD) and start
hemodialysis. The objective is to identify factors inﬂuencing early
nephrology care, deﬁned as visiting a nephrologist from 4 to 12
months prior to hemodialysis initiation among elderly ESRD
patients. METHODS: The study population consists of patients
initiating hemodialysis in the years 1996–1999, aged 67+ years
and having Medicare Part B coverage in the fee-for-service
system in the 2nd year prior to dialysis initiation. Patients’ char-
acteristics were obtained from Centers for Medicare & Medic-
aid Services form 2728 ﬁles. Comorbidities and hospital
utilization were generated from Medicare Part A and/or Part B
claims. Physician visits including early nephrology care and
access to non-nephrologist physicians and nephrologists practic-
ing in a local area, deﬁned as an area 30 miles within a patient’s
residence ZIP code, were computed with Medicare Part B physi-
cian/supplier ﬁles and US 2000 Census data. RESULTS: About
33.79% of 91,189 elderly patients received early nephrology
care before starting hemodialysis. Logistic regressions indicated
that patients who were male, had hypertension, anemia, more
hospital admissions in the year before initiating dialysis, lived in
an area with more nephrologists per 1000 prevalent elderly
ESRD patients were more likely to obtain early nephrology care.
Patients older than 76 years, having diabetes, living in an area
with more non-nephrologist physicians per 10,000 population
had a lower likelihood of getting early nephrology care. Patients
residing in areas 12 miles or more away from the nearest
nephrologist had a smaller odds ratio of receiving early nephrol-
ogy care compared to patients living in an area less than 4 miles
away. CONCLUSIONS: Elderly ESRD patients’ characteristics
and access to local non-nephrologist physicians and nephrolo-
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OBJECTIVES: Zero-mass cost values, heteroskedasticity and re-
transformation are three common problems in health care expen-
diture models. In this paper, we applied recently proposed
methodology which deals with these three common problems
simultaneously. METHODS: Two parts models are suitable for
estimating right-skewed cost data. The main complication in this
case is the retransformation where smearing estimation fails
when there is evidence of heteroskedasticity which is very
common in analyzing health care expenditures. Recently pro-
posed “internal” and “external” estimators remove the bias in
log-transformed two part model with heteroskedasticity. First,
we estimate probability of having zero cost by logit (h), and then
create internal weight which is equal to (1-h)/(1-m) where m is
the average of the estimated probabilities and external weight
which is equal to (1-h). The retransformed cost for the non-zero
cost sample is multiplied by internal weight to get internal trans-
formed cost. External transformed cost can be calculated by
averaging external weighted cost over the no-zero cost sample.
RESULTS: The method is applied to Market Scan Data which
based upon patients with chronic kidney disease. Total inpatient
cost is estimated using log transformed two part model. Fifty-six
percent of the patient sample had zero cost. White Test proved
heteroskedasticity. Internal and External estimators yield similar
results (p = 0.852) but they were statistically different from 
the standard estimator which ignores heteroskedasticity in 
re-transformation (p = 0.000). CONCLUSIONS: Re-
transformation bias in two part models can be eliminated using
internal and external weighted estimators.
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OBJECTIVES: Health outcome measurement in patients with
Overactive Bladder (OAB) is largely based on condition speciﬁc
measures such as the OAB-q and King’s Health Questionnaire
(KHQ). Generic preference-based measures of health (e.g. SF-36
and EQ-5D) have not shown to be sensitive in OAB patients.
The condition speciﬁc measures are not preference based; a
requirement for QALY estimation. To date, cost-effectiveness
studies of treatments for OAB have relied upon treatment per-
sistency as a proxy for health outcome. However, recent research
has shown it is possible to estimate a preference-based single
index using the KHQ. The purpose of this study was to test the
application of such an index by estimating and comparing
changes in quality adjusted life years (QALYs) in a population
of OAB patients either receiving pharmacologic treatment for
OAB or not. METHODS: Patients’ KHQ scores were trans-
formed into a 5 dimensional health state classiﬁcation amenable
to valuation (role limitation, physical limitation, social limita-
tion, emotions and sleep). Patient level data, including KHQ
scores were taken from a sample of patients with OAB in the UK
and Germany. The modelled beta coefﬁcients associated with
each level of each dimension was applied to the health state clas-
siﬁcations. Changes in utility were then estimated by measuring
the difference between results at 2 different time points, baseline,
and 12 weeks after treatment. RESULTS: Data from 175 patients
